Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Agomelatine (AGO178C)

First Posted Date: 2010-04-27

Last Posted Date: 2020-12-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 582

Registration Number: NCT01110889

Locations: 🇺🇸
The Ohio State University - Harding Hospital, Columbus, Ohio, United States
🇺🇸
KRK Medical Research, Dallas, Texas, United States
🇺🇸
FutureSearch Trials of Dallas, Dallas, Texas, United States

and more 45 locations

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

Phase 2

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AIN457A

First Posted Date: 2010-04-23

Last Posted Date: 2021-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT01109940

Locations: 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced or Metastatic Basal Cell Carcinoma
Recurrent or Refractory Medulloblastoma
Advanced Solid Tumors

Interventions: Drug: LEQ506

First Posted Date: 2010-04-20

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT01106508

Locations: 🇺🇸
University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Phase 3

Completed

Conditions: Cryopyrin Associated Periodic Syndrome

First Posted Date: 2010-04-16

Last Posted Date: 2017-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT01105507

Locations: 🇨🇦
Alberta Children's Hospital, Department of Pediatrics, Calgary, Canada
🇨🇦
Queen Elizabeth II Hospital, Halifax, Canada

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: QAV680
Drug: QAV680 Placebo

First Posted Date: 2010-04-13

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01103037

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇺🇸
American Health Research, Charlotte, North Carolina, United States
🇺🇸
West Coast Clinical Trials, Cypress, California, United States

and more 1 locations

A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: QAV680 + Cetirizine Placebo
Drug: QAV680 + Cetirizine
Drug: Cetirizine + QAV680 Placebo
Drug: QAV680 Placebo + Cetirizine Placebo

First Posted Date: 2010-04-13

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT01103050

Locations: 🇨🇦
Novartis Investigative Site, Ontario, Canada

Safety and Efficacy of LCL161 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: LCL161

First Posted Date: 2010-04-05

Last Posted Date: 2012-08-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 71

Registration Number: NCT01098838

Locations: 🇺🇸
UNC/ Lineberger Comprehensive Cancer Center Dept. of LinbergerCancerCtr(2), Chapel Hill, North Carolina, United States
🇺🇸
Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville, Tennessee, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: CAD106
Biological: Placebo
Biological: Alum
Biological: MF59

First Posted Date: 2010-04-01

Last Posted Date: 2021-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 177

Registration Number: NCT01097096

Locations: 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Phase 3

Terminated

Conditions: Uveitis

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2010-03-30

Last Posted Date: 2015-11-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01095250

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

38 Week Extension Study to CAIN457C2303

Phase 3

Terminated

Conditions: Uveitis

Interventions: Drug: AIN457
Drug: Placebo AIN457

First Posted Date: 2010-03-26

Last Posted Date: 2016-02-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT01093846

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy